A practical reference on actin-binding motif: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-06-30. Anything still debated is marked as such rather than presented as settled.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Typical form for short synthetic peptides |
| Solubility class | Freely soluble in water and aqueous buffer | Dissolution aided by gentle mixing, not vigorous shaking |
| Typical storage temperature | −20 °C, desiccated | −80 °C used for long-term holding |
| Common analytical method | Reverse-phase HPLC with UV detection near 214 nm | Identity confirmed separately by mass spectrometry |
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming varies between suppliers and publications |
Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
Chemistry Tree: Paul J. Flory Details Paul Flory on Nobelprize.org A short autobiography of Paul Flory Nobel lecture by Paul Flory Mangravite, Andrew (2001). "Finding Aid to the Paul J. Flory papers, 1931–1985 bulk 1950–1978". Science History Institute. Retrieved March 27, 2018. Click on 'Paul J. Flory papers finding aid' for full finding aid. Paul J. Flory papers at the Hoover Institution Archives National Academy of Sciences Biographical Memoir
Plasma protein binding refers to the degree to which medications attach to blood proteins within the blood plasma. A drug's efficacy may be affected by the degree to which it binds. The less bound a drug is, the more efficiently it can traverse or diffuse through cell membranes. Common blood proteins that drugs bind to are human serum albumin, lipoprotein, glycoprotein, and α, β‚ and γ globulins.
=== Pharmacodynamics === In gout, probenecid competitively inhibits the reabsorption of uric acid through the organic anion transporter (OAT) at the proximal tubules. This leads to preferential reabsorption of probenecid back into plasma and excretion of uric acid in urine, thus reducing blood uric acid levels and reducing its deposition in various tissues. Probenecid also inhibits pannexin 1. Pannexin 1 is involved in the activation of inflammasomes and subsequent release of interleukin-1β causing inflammation. Inhibition of pannexin 1 thus reduces inflammation, which is the core pathology of gout.
Sources: en.wikipedia.org
Cheating in sports McLaren Report Mitchell Report Doping at the Olympic Games Cheating at the Paralympic Games Doping in Russia Doping in China Doping in the United States Doping in East Germany BALCO scandal Caffeine use for sport Cannabis and sports Concussions in sport Doping in pigeon racing Equine drug testing Gene doping Mechanical doping Stem cell doping Technology doping
Aspartame is an artificial, non-saccharide sweetener commonly used as a sugar substitute in foods and beverages. It is 200 times sweeter than sucrose, and is a methyl ester of the aspartic acid/phenylalanine dipeptide with brand names NutraSweet, Equal, and Canderel. Discovered in 1965, aspartame was approved by the US Food and Drug Administration (FDA) in 1974 and re-approved in 1981 after its initial approval was briefly revoked. Aspartame is one of the most studied food additives in the human food supply. Reviews by over 100 governmental regulatory bodies found the ingredient safe for consumption at the normal acceptable daily intake limit. A number of health organizations such as the American Heart Association, American Diabetes Association, and American Cancer Society are supportive of its use consistent with other approved low-calorie sweeteners.
While P-51s used 110-US-gallon (420 L) drop tanks over Europe, for Japan they frequently used 165-US-gallon (620 L) drop tanks which allowed more loitering time over Japan. While USAAF B-17 and B-24 bombers in Europe were arranged in combat box formations, over Japan the B-29s formed a stream that could stretch up to 200 miles. The escorting P-51s formed three Tar-Cap (Target Combat Air Patrol) squadrons, two squadrons flying on one side of the B-29 stream and the third on the other side, each squadron being 2,000 feet above and 4,000 to 5,000 feet laterally from the bomber stream. Compared to its Japanese adversaries, the P-51 largely outclassed the Imperial Japanese Army Air Service's aging A6M Zero (the most numerous Japanese fighter available), as the A6M's poor high-altitude performance put it at a disadvantage in the P-51's favorable performance envelope. When the P-51 was used for interdiction or strike missions, the A6M was slower but could still out-turn or out climb the P-51 at low to medium altitude. Newer Japanese designs were potent but too few in number. The Kawanishi N1K-J Shiden was fast and agile, but not effective as an interceptor due to a poor rate of climb and reduced engine performance at high altitude. The Imperial Japanese Army Air Service's Nakajima Ki-84 Hayate had performance and an operation ceiling that could match the P-51, however the Ki-84 suffered from manufacturing defects, and its high-maintenance Nakajima Homare engine could not reach its full potential due to lack of ample high-octane fuel.
=== Buffer composition === The ionic strength of the buffer used can affect the ligation. The kinds of cations presence can also influence the ligation reaction, for example, excess amount of Na+ can cause the DNA to become more rigid and increase the likelihood of intermolecular ligation. At high concentration of monovalent cation (>200 mM) ligation can also be almost completely inhibited. The standard buffer used for ligation is designed to minimize ionic effects.
Sources: en.wikipedia.org
=== Glycogenesis === Glycogenesis refers to the process of synthesizing glycogen. In humans, glucose can be converted to glycogen via this process. Glycogen is a highly branched structure, consisting of the core protein Glycogenin, surrounded by branches of glucose units, linked together. The branching of glycogen increases its solubility, and allows for a higher number of glucose molecules to be accessible for breakdown at the same time. Glycogenesis occurs primarily in the liver, skeletal muscles, and kidney. The Glycogenesis pathway consumes energy, like most synthetic pathways, because an ATP and a UTP are consumed for each molecule of glucose introduced.
National authorities could be justified in refusing to reimburse patients for medical services abroad if the health care received at home was without undue delay, and it followed "international medical science" on which treatments counted as normal and necessary. The Court requires that the individual circumstances of a patient justify waiting lists, and this is also true in the context of the UK's National Health Service. Aside from public services, another sensitive field of services are those classified as illegal. Josemans v Burgemeester van Maastricht held that the Netherlands' regulation of cannabis consumption, including the prohibitions by some municipalities on tourists (but not Dutch nationals) going to coffee shops, fell outside article 56 altogether. The Court of Justice reasoned that narcotic drugs were controlled in all member states, and so this differed from other cases where prostitution or other quasi-legal activity was subject to restriction. If an activity does fall within article 56, a restriction can be justified under article 52, or by overriding requirements developed by the Court of Justice. In Alpine Investments BV v Minister van Financiën a business that sold commodities futures (with Merrill Lynch and another banking firms) attempted to challenge a Dutch law that prohibiting cold calling customers. The Court of Justice held the Dutch prohibition pursued a legitimate aim to prevent "undesirable developments in securities trading" including protecting the consumer from aggressive sales tactics, thus maintaining confidence in the Dutch markets.
=== Geena Williams-Conner === Geena Williams-Conner is played by Maya Lynne Robinson (Rae'Ven Larrymore Kelly in season 7 and Xosha Roquemore in season 10). The African-American wife of D.J. and mother of Mary; she is, like D.J., a military veteran. The character was introduced in a 1994 Roseanne episode wherein D.J. must kiss her for a school play, but is reluctant to do so because she is black (race). D.J. overcomes his prejudices and kisses her for the play; she is not seen on the original show again. In the Season 10 revival, it is revealed that Geena had married D.J., and while D.J. is home raising their daughter, she is still an active-duty soldier. She was a main character in season one of The Conners, having been discharged from the military after a tour in Afghanistan. In Season 2, she is called into active duty again. In an interview with MEAWW, Robinson explained that the show did not have her character return as a regular, and that she was joining another sitcom as a main character in The Unicorn.
Sources: en.wikipedia.org
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.
Not necessarily. Some vendors use the name for the full 43-residue protein, while others apply it to a short actin-binding fragment or to a related tetrapeptide. The sequence should be confirmed from documentation rather than assumed from the label.
No thymosin beta-4 fragment holds marketing approval as a medicine in major jurisdictions. Material offered for sale is typically labelled for laboratory research only.
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.